Neurophotonics Market Report 2026

The neurophotonics market size has grown rapidly in recent years. It will grow from $1.92 billion in 2025 to $2.14 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing demand for noninvasive neuroimaging, growing adoption of optical imaging in neuroscience research, rising prevalence of neurological disorders driving diagnostic needs, expanding use of brain mapping technologies in academic institutions, and growing investment in biomedical photonics by government and private organizations.

The neurophotonics market size is expected to see rapid growth in the next few years. It will grow to $3.28 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to increasing focus on early detection of mental health and neurodegenerative diseases, rising adoption of optical neuromodulation for therapeutic applications, growing integration of artificial intelligence in neuroimaging data analysis, expanding clinical trials adopting photonic brain monitoring tools, and increasing commercialization of advanced laser-based neurotechnology platforms. Major trends in the forecast period include technology advancements in optical coherence and functional spectroscopy, innovations in multimodal brain imaging systems, rapid developments in noninvasive neural stimulation technology, continuous research and development in photonic brain signal monitoring, and integration of cloud-based and real-time analytics for neuroscience data.

The growing demand for non-invasive imaging techniques is expected to drive the growth of the neurophotonics market in the coming years. Non-invasive imaging techniques allow researchers and clinicians to visualize internal neurological structures and activity without surgery or body penetration, using technologies such as MRI, fMRI, EEG, MEG, and optical imaging. This rising demand is fueled by the need in neuroscience research for safer, repeatable, and high-resolution tools that can study brain structure and function without risk to subjects. Neurophotonics addresses this demand by providing advanced light-based imaging technologies that enable precise visualization of neural circuits and real-time monitoring of brain activity. For example, in July 2025, the National Institutes of Health (NIH) BRAIN Initiative, a US-based government research program, reported that the ultra-high-resolution Connectome 2 MRI scanner was developed in 2023. The neurophotonics market is projected to grow at a compound annual growth rate (CAGR) of approximately 10.7-11.2% from 2025 to 2033, with an estimated market size of around USD 5.1 billion by 2033 as light-based neuroimaging sees broader clinical and research adoption. Consequently, the rising demand for non-invasive imaging techniques is propelling the growth of the neurophotonics market.

Leading companies in the neurophotonics market are focusing on developing advanced tools, such as optogenetic and optical sensor instruments, to improve neural activity measurement, control, and translational neuroscience research. Optogenetic and optical sensor instruments are engineered light delivery systems and optical sensors that can stimulate and record neural activity at cellular resolution, providing vital insights into nervous system function. For example, in September 2025, the NIH Common Fund Venture Program awarded grants under the Advancing Non-Invasive Optical Imaging Approaches for Biological Systems initiative to support the development of real-time optical imaging systems capable of deep tissue imaging and molecular contrast, including techniques such as synthetic wavelength imaging. These federally funded programs promote the creation of next-generation neurophotonics tools that industry players can adopt and commercialize for both research and clinical applications.

In October 2023, MBF Bioscience, a US-based provider of quantitative imaging solutions for bioscience research and neuroscience applications, acquired Neurophotometrics LLC for an undisclosed sum. This acquisition enables MBF Bioscience to expand its neurophotonics capabilities by incorporating Neurophotometrics’ optical instrumentation for fiber photometry and neural activity imaging, strengthening its support for advanced neuroscience research. Neurophotometrics LLC is a US-based developer of specialized optical systems designed to record and analyze neural activity in research settings.

Major companies operating in the neurophotonics market are Hitachi Ltd., Olympus Corporation, Coherent Corp., Bruker Corporation, HORIBA Ltd., Hamamatsu Photonics K.K., Leica Microsystems GmbH, Thorlabs Inc., Spectra-Physics, NeuroLight Technologies Ltd., Inscopix Inc., NeuroNexus Technologies Inc., Intelligent Imaging Innovations Inc., Femtonics Limited, NIRx Medical Technologies LLC, Hemophotonics S.L., Carl Zeiss AG, Artinis Medical Systems B.V., Plexon Inc., Vielight Inc., Nanoscope Technologies LLC, Neurophotometrics Ltd.

North America was the largest region in the neurophotonics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurophotonics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurophotonics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the neurophotonics market by increasing costs of imported lasers, optical sensors, photonic components, imaging equipment, and precision electronics. research institutions and healthcare providers in north america and europe are most affected due to dependence on imported high-end optical systems, while asia-pacific faces higher production costs for photonics equipment. these tariffs are increasing capital expenditure for research and clinical deployments. however, they are also encouraging regional photonics manufacturing, domestic technology development, and localized supply chains for advanced neuroimaging solutions.

Neurophotonics is the science and technology that uses light-based methods - such as optical imaging, spectroscopy, and laser stimulation - to study, monitor, and modulate the structure and function of the brain and nervous system. It allows non-invasive or minimally invasive visualization of neural activity, supporting progress in brain mapping, diagnostics, mental health research, and the treatment of neurological disorders.

The primary components of neurophotonics include devices and equipment, software and analytics platforms, consumables and accessories, and services. Devices include optical systems used to visualize and manipulate neural activity with high precision. Technologies include OCT, laser stimulation, photoacoustic imaging, optogenetics, fluorescence imaging, fNIRS, and two-photon microscopy. Distribution includes online sales, distributors, and direct supply. Applications include research, diagnostics, and therapeutics across academic institutes, hospitals, and biotech companies.

The neurophotonics market consists of revenues earned by entities providing technologies, systems, and solutions such as optical neuroimaging tools, brain stimulation devices, photonic sensors, laser-based diagnostics, and biomedical optics integration. The market value includes the value of related equipment and software sold by the solution providers or included within their technology offerings. The neurophotonics market includes sales of optical imaging systems, laser sources, photodetectors, fiber-optic probes, microscopes, and related neuroimaging instruments. Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream distributors, wholesalers, and research institutions) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.